BioSpace News Archive

Otsuka and Lundbeck won approval Friday for Abilify Asimtufii, a long-acting injectable that provides two months of symptom relief in patients with schizophrenia or bipolar I disorder.

The Oncologic Drugs Advisory Committee voted 11–1 supporting Merck’s and AstraZeneca’s PARP inhibitor for metastatic castration-resistant prostate cancer patients with BRCA mutations.

Japanese biopharma scoops up Iveric’s investigational drug for age-related blindness disease. The drug, which trails Apellis’ Syfovre, is awaiting FDA approval with a decision expected by August.

RadNet, Inc., announced that it has received FDA clearance for the third-generation release of its Quantib Prostate™ 3.0 MRI artificial intelligence software, further enhancing the offering with new and updated tools.

Systimmune, Inc. announced that it will present clinical data from its lead programs at the ASCO Annual Meeting 2023 in Chicago in June.

Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:00 a.m. ET to discuss results for the first quarter 2023 and to provide a corporate update.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022.

TFF Pharmaceuticals, Inc. announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems program to develop next-generation countermeasures for military and healthcare personnel.

Galera Therapeutics, Inc. today announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective immediately.